FDA decision: Lilly’s oral SERD combo moves into second-line breast cancer

The FDA approved Eli Lilly’s oral selective estrogen receptor degrader (SERD) combination regimen, Inluriyo, for certain patients in the second-line setting for metastatic breast cancer. The approval adds a new option built around an all-oral SERD approach, with the regimen intended for patients who have progressed beyond prior therapy.